Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 12/20 | 1.00 |
| ▸ | RAB9A | P51151 | 12/20 | 1.00 |
| ▸ | MAPT | P10636 | 9/20 | 1.00 |
| ▸ | MEN1 | O00255 | 7/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 7/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 4/20 | 1.00 |
| ▸ | NFKB2 | Q00653 | 4/20 | 1.00 |
| ▸ | RELA | Q04206 | 4/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.76 |
| ▸ | HPGD | P15428 | 1/20 | 0.76 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.72 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.72 |
| ▸ | POLB | P06746 | 5/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.66 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.65 |
| ▸ | ACP1 | P24666 | 1/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28640786 | 0.98 | NPC1 (0.97) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL23069082 | 0.94 | NPC1 (0.89) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL27634788 | 0.92 | NPC1 (0.84) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL32674581 | 0.92 | NPC1 (0.84) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL540965 | 0.88 | MAPT (0.79) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL2245925 | 0.88 | NPC1 (0.79) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL4922739 | 0.88 | NPC1 (0.79) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL11993580 | 0.86 | NPC1 (0.75) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL27259246 | 0.86 | NPC1 (0.75) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL4537019 | 0.85 | NPC1 (0.73) | NPC1RAB9AMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199562-A1 | UREA DERIVATIVES FOR TREATING UVEAL MELANOMA | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-06-20 | — | — | US | claimed |
| EP-4322944-A1 | UREA DERIVATIVES FOR TREATING UVEAL MELANOMA | Centre National de la Recherche Scientifique (FR) | 2024-02-21 | — | — | EP | claimed |
| WO-2022219123-A1 | UREA DERIVATIVES FOR TREATING UVEAL MELANOMA | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-10-20 | — | — | WO | claimed |
| US-4208419-A | N-Heterocyclic ureas as immune regulants | ELI LILLY AND COMPANY (US) | 1980-06-17 | — | — | US | claimed |
| US-20240199562-A1 | UREA DERIVATIVES FOR TREATING UVEAL MELANOMA | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-06-20 | — | — | US | disclosed |
| EP-4322944-A1 | UREA DERIVATIVES FOR TREATING UVEAL MELANOMA | Centre National de la Recherche Scientifique (FR) | 2024-02-21 | — | — | EP | disclosed |
| CN-107427501-B | Methods of treating cancer by combination use | 第一三共株式会社 | 2023-12-01 | — | — | CN | disclosed |
| US-11731985-B2 | Compositions and methods for treating cancer | HB THERAPEUTICS INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731985-B2 | Compositions and methods for treating cancer | HB THERAPEUTICS INC. (US) | 2023-08-22 | — | — | US | disclosed |
| CN-115515582-A | Combination therapy for acute myeloid leukemia | 细胞基因公司 | 2022-12-23 | — | — | CN | disclosed |
| WO-2022219123-A1 | UREA DERIVATIVES FOR TREATING UVEAL MELANOMA | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-10-20 | — | — | WO | disclosed |
| CN-115175937-A | Combination of anti-TIM-3 antibody MBG453 and anti-TGF-beta antibody NIS793 with or without decitabine or anti-PD-1 antibody, gabapentin, for the treatment of myelofibrosis and myelodysplastic syndrome | 诺华股份有限公司 | 2022-10-11 | — | — | CN | disclosed |
| US-20110034463-A1 | TYPE III SECRETION INHIBITORS, ANALOGS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-02-10 | — | — | US | disclosed |
| WO-2009145829-A1 | TYPE III SECRETION INHIBITORS, ANALOGS AND USES THEREOF | UNIVERSITY OF MASSACHUSETTS (US) | 2009-12-03 | — | — | WO | disclosed |
| US-4208419-A | N-Heterocyclic ureas as immune regulants | ELI LILLY AND COMPANY (US) | 1980-06-17 | — | — | US | disclosed |
| US-4171364-A | ANTIBODY INHIBITORS | ELI LILLY AND COMPANY (US) | 1979-10-16 | — | — | US | disclosed |
| US-4153709-A | BENZIMIDAZOLES OR NAPHTHIMIDAZOLES | ELI LILLY AND COMPANY (US) | 1979-05-08 | — | — | US | disclosed |
| US-4088768-A | BENZIMIDAZOLYL, BENZOTHIAZOLYL, AND BENZOXAZOLYL UREAS AND THIOUREAS | ELI LILLY AND COMPANY (US) | 1978-05-09 | — | — | US | disclosed |
| US-4046770-A | IMMUNE REGULANTS | ELI LILLY AND COMPANY (US) | 1977-09-06 | — | — | US | disclosed |
| US-3932434-A | IMMUNOSUPPRESSANTS | ELI LILLY AND COMPANY (US) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731985-B2 | Compositions and methods for treating cancer | VHL, TP53, NUDT1 | NPC1 424/4885RAB9A 3882/4885MAPT 1476/4885 |
| US-20240199562-A1 | UREA DERIVATIVES FOR TREATING UVEAL MELANOMA | UACA, SLC14A1, MITF | NPC1 2159/4885RAB9A 1206/4885MAPT 409/4885 |
| US-20110034463-A1 | TYPE III SECRETION INHIBITORS, ANALOGS AND USES THEREOF | GBA3, CLPP, PEX3 | NPC1 1902/4885RAB9A 438/4885MAPT 3404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.